MS: WuXi AppTec's Inclusion in 1260H List Does Not Alter Private Sector Cooperation Resilience

Overview

Regarding the US Department of Defense's inclusion of WuXi AppTec in the 1260H 'Chinese Military Companies' list on June 8, Morgan Stanley issued a quick comment pointing out that the substantial impact on the stock price may be limited. The firm maintains its 'Overweight' rating and HKD 155 target price unchanged. The core logic is that the 1260H list mainly restricts US government-related business. Considering the deep binding between China and the US in drug R&D and the continuous rise in the company's commercial projects in hand, cooperation in the private sector is unlikely to decouple as a result.

Core views

On the actual impact boundaries of the 1260H list: The research report emphasizes that the direct constraints of this list are mainly on US government business procurement and investment, which does not equate to comprehensive sanctions or private sector decoupling. For reference, this updated list covers leading Chinese enterprises across a wide range of industries, including Alibaba, BYD, and Baidu, showing a generalized coverage characteristic. WuXi AppTec has already issued a pre-market statement denying any military affiliation and will take action to challenge this designation. Business Resilience and Fundamental Support: Despite geopolitical noise, the company's commercial cooperation is steadily expanding. As of Q1 2026, WuXi AppTec holds 89 commercial production contracts for launched new drugs, and the number of Phase III clinical projects has increased to 94. Financial data shows that in 2025, the proportion of revenue from US customers further increased to 72% (64% in 2024), indirectly confirming that the dependence of US private pharmaceutical companies on the Chinese CXO supply chain has not decreased due to geopolitical friction. Valuation and Rating Anchors: Based on the above judgments, the institution has not adjusted earnings forecasts or valuation parameters. The H-share target price of HKD 155 is derived from the A-share target price using a 1:1 exchange rate assumption. The A-share valuation uses the Discounted Cash Flow method (WACC 10%, perpetual growth rate 4%). The current stock price corresponds to approximately 28% upside potential, with the rating maintained at 'Overweight'.

Analysis framework

The institution adopted a dual analysis framework of 'policy substance dissection + high-frequency business data verification'. First, by distinguishing the legal scope of application of the 1260H list (government vs. private) to strip away market sentiment panic; second, using quarterly-level commercialization and Phase III clinical project numbers as leading indicators to verify whether geopolitics has substantially damaged the company's order acquisition capability; finally, combining key political calendars (such as Congressional deliberations, high-level meetings, and bill implementation) to construct event-driven observation windows, rather than just doing static risk qualitative analysis.

Methodology notes

• Event Gaming and Behavioral FinanceEvent-driven analysis

  Stratification of Policy List Applicability

  When assessing the impact of geopolitical lists (such as 1260H) on listed companies, they should not be viewed as homogeneous negative factors. It is necessary to distinguish whether their legal effect is limited to 'government entity procurement/investment' or extends to 'all-market private transactions'. This research report reaches the differentiated conclusion that the decoupling risk of private CXO business is controllable by defining that 1260H mainly constrains government business.

• Industry/Industrial Analysis FrameworkUpstream-Midstream-Downstream Transmission

  CXO Order Funnel as a Leading Indicator of Prosperity

  For the pharmaceutical outsourcing (CXO) industry, current revenue often reflects historical orders, while 'commercial project count' and 'Phase III clinical project count' are the leading indicators of future revenue. By tracking the quarterly trend changes of these two indicators, the research report verifies whether the company's ability to acquire long-term overseas orders is impaired under geopolitical pressure, which is more forward-looking than simply looking at short-term financial reports.

• Valuation MethodDCF Discounted Cash Flow

  A/H Share Premium and Exchange Rate Anchoring

  For companies listed on both A-shares and H-shares, when H-share liquidity or pricing is significantly interfered with by external factors, institutions sometimes first perform DCF absolute valuation on the fundamentally purer A-shares, and then convert them into an H-share target price using a fixed or dynamic exchange rate. This report adopts a 1:1 exchange rate assumption, mapping the intrinsic value of A-shares to the H-share pricing benchmark.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec (2359.HK / 603259.SS)

  Direct subject involved in the 1260H list, but the research report believes the substantial business impact is limited

  Strengths

  Commercialization and Phase III clinical project counts grew against the trend; high stickiness of US private customers (revenue share 72%); the company has initiated legal challenge procedures

  Weaknesses

  Inclusion in the 1260H list may trigger passive reduction by some compliance-sensitive funds; high dependence on the US market makes it susceptible to fluctuations in bilateral relations

  Comparison

  Other companies included in the same batch include Alibaba, BYD, and Baidu, indicating broad coverage of the list rather than a precise strike against a single enterprise

  Risks

  Talent loss risk; pressure on US business profit margins; intensified global competition; intellectual property protection or reputational risks; escalation of geopolitical risks

Key data

• H-Share Target Price155.00 HKDMaintained unchanged, implying 28% upside potential
• US Customer Revenue Share72%2025 data, further increased from 64% in 2024
• Commercial Project Count89Number of commercial production contracts for launched new drugs
• Phase III Clinical Project Count94As of the end of Q1 2026, showing a continuous growth trend
• Valuation Parameter (WACC)10%A-share DCF model assumption, perpetual growth rate of 4%

Impact & implications

The research report believes that the update of the 1260H list is more of a signal release at the geopolitical level, rather than a devastating blow to WuXi AppTec's commercial fundamentals. As long as the complementary structure of Sino-US innovative drug R&D remains unchanged, and the company can continuously prove its irreplaceability in the private sector, valuation suppression is expected to repair over time. Investors should shift their attention from the single list event to subsequent legislative processes and marginal changes in the company's order data.

Risks

• Fed rate pivot driving recovery in biotech financing (upside risk)
• Government issuance of favorable policies (upside risk)
• Margin expansion driven by improved operational efficiency (upside risk)
• Talent loss
• Profit margin pressure on US business
• Intensified global market competition
• Intellectual property protection issues or reputational damage
• Geopolitical risks worsening beyond expectations

What to watch

• Submission status of relevant US Congressional procedures in late July
• Trump-Xi meeting in Washington in September
• Progress on the passage of the US National Defense Authorization Act (NDAA 2027), i.e., the Biosecure Act, in December